Kura Oncology, Inc. income statement

In fiscal 2025, Kura Oncology, Inc. reported revenue of $67.5m, up 25.2% on the year before, operating income of −$304m (a -449.9% margin) and net income of −$279m, or −$3.18 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Kura Oncology, Inc.: income statement, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	0	54	67	77
Research and development	115	170	251	259
Selling, general and administrative	51	77	120	—
Operating income	−166	−193	−304	−318
Interest expense	2	2	2	1
Income before tax	−153	−172	−278	−297
Income tax	0	2	0	0
Net income	−153	−174	−279	−297
Diluted EPS	−$2.08	−$2.02	−$3.18	−$3.36
Diluted shares (average)	73m	86m	88m	88m
EBITDA	−165	−192	−303	−317

US$ millions unless shown otherwise. Fiscal quarters.

Kura Oncology, Inc.: income statement, quarterly
Quarter	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	14	15	21	17	18	21
Cost of revenue	—	—	—	—	0	0
Gross profit	—	—	—	—	18	21
Research and development	56	63	68	64	65	62
Selling, general and administrative	23	25	—	—	32	32
General and administrative	—	—	33	—	—	—
Operating income	−65	−73	−80	−86	−79	−73
Interest expense	0	0	0	0	0	0
Income before tax	−57	−66	−74	−81	−73	−68
Income tax	0	0	0	0	0	0
Net income	−57	−66	−74	−81	−73	−68
Diluted EPS	−$0.66	−$0.75	−$0.85	−$0.92	−$0.83	−$0.77
EBITDA	−64	−72	−80	−86	−78	−73

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ADCT vs KURA ASMB vs KURA AAPG vs KURA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kura Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kura Oncology, Inc.